This new subcutaneous anticoagulant, abelacimab, binds to the inactive form of FXI and blocks its activation by FXII. This drug seems significantly safer than DOAC’s in terms of bleeding risk. So much so that the study was stopped early due to a greater-than-expected reduction in bleeding events in the study arm. I hope this drug is also going to be studied for the treatment of VTE.
Full publication of the ESOPEC trial which was presented at ASCO-2024. Essentially perioperative FLOT beat preoperative carbo/taxol/XRT. One call out is that this study began before the era of using postoperative IO therapy for those with residual disease at the time of esophagectomy after neoadjuvant chemoradiation. Also, I would suggest that for bulky or node+ tumors, it may be worthwhile to consider a TNT-type approach as only ~50% of patients complete the four postoperative cycles of FLOT.
Monoclonal antibody targeting growth differentiation factor 15, a cytokine that causes cachexia in cancer. This one has promising results.
Trimodality therapy is an effective potential alternative to radical cystectomy for recurrent high-grade T1 urothelial cancer of the bladder.
Similar outcome in overall survival. In some cases, chemotherapy was added to radiation ( LN positive). Also, some required adjuvant chemotherapy and radiation.
THC helped, but had more adverse events, (sedation, dizziness, etc.) THC was in addition to other prophylactic antiemetic, improved response rate from 8 to 24%.
Pembrolizumab in addition to chemotherapy DID NOT help, recall now we have new approval for those patients (datopotamab).
This is another supportive care study that confirms the benefit of Naldemdine in preventing constipation induced by opioids.
No oxaliplatinum in stage 2 colon cancer, even high-risk patients, by the way, De Gramont is one of the authors (father of FOLOFX reigmens).
Using AI to detect immunotherapy adverse events in hospital admissions was better than using ICD codes, another application for AI. We will see more AI studies in the next couple of years.